Cariprazine Effective in AD-Resistant MDD

November 2, 2022 · Posted in Current Treatments 
Cariprazine Effective in AD-resistant MDD

Maletic, V, et al. reported on Efficacy of Adjunctive Cariprazine Across Individual Depressive Symptoms in Major Depressive Disorder:  A Post-Hoc Analysis. Poster presented at Psych Congress 2022; September 17-20, 2022.

“With 751 patients (502 on CARIPRAZINE (CAR) and 249 on PBO), the LSMD (95% CI) score change from baseline to week 6 was significant in favor of CAR. Items of the MADRS scale were assessed individually over the course of the study, including apparent sadness, reported sadness, reduced appetite, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts, showing improvement compared to PBO. “


Comments are closed.